Ilias Houda, MD, PhD Candidate, on Results of an EORTC Survey on NSCLC Resectability
IASLC 2023 WCLC
Ilias Houda, MD, PhD Candidate, of Amsterdam University Medical Centers, discusses the differing opinions of thoracic surgeons when it comes to resection for stage III non–small cell lung cancer (NSCLC). The international EORTC survey showed there is no consensus, although respondents were more likely to consider some stage III TNM combinations to be potentially resectable.
The ASCO Post Staff
Gilberto de Lima Lopes, Jr, MD, MBA, of the Sylvester Comprehensive Cancer Center at the University of Miami, comments on four presentations from the 2023 World Conference on Lung Cancer for which he served as discussant: the global landscape of three types of lung cancer (squamous cell, adenocarcinoma, and small cell); findings from the Australian Registry and Biobank of Thoracic Cancers; the Registry of Genetic Alterations of Taiwan by comprehensive next-generation sequencing; and treatment decisions in octogenarians with non-small cell lung cancer.
The ASCO Post Staff
David H. Harpole, Jr, MD, of Duke University Medical Center, discusses further exploratory analyses of patients with EGFR-mutated resectable non–small cell lung cancer (NSCLC) enrolled in the phase III AEGEAN study. In this trial, perioperative durvalumab plus neoadjuvant chemotherapy, vs neoadjuvant chemotherapy alone, significantly improved event-free survival and pathologic complete response (Abstract OA12.06).
The ASCO Post Staff
Ticiana A. Leal, MD, of Winship Cancer Institute at Emory University, discusses phase III findings from the LUNAR study of tumor treating fields (electric fields that disrupt cellular processes and lead to cell death) combined with the standard of care in patients with metastatic non–small cell lung cancer (NSCLC) after relapse on platinum treatment. The survival benefit of this regimen was especially profound in patients with tumor PD-L1 expression who received an immune checkpoint inhibitor as the standard of care, according to Dr. Leal (Abstract OA22.05).
The ASCO Post Staff
Xiuning Le, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses results of the VISION trial, the largest on-treatment liquid biopsy biomarker data set of a MET inhibitor in patients with MET exon 14 non–small cell lung cancer (NSCLC). Tepotinib showed durable efficacy in this population.
The ASCO Post Staff
Yasir Y. Elamin, MD, of The University of Texas MD Anderson Cancer Center, discusses findings from the BRIGHTSTAR study, in which brigatinib with local consolidative therapy was found to be safe in patients with ALK-rearranged advanced non–small cell lung cancer. This regimen yielded promising outcomes when compared with historical outcomes with brigatinib alone (Abstract OA22.04).
